List of Artificial Intelligence Companies in Japan - 7

Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.

Providing high-sensitivity quantification services for ultra-trace proteins, we will support research and development of pharmaceuticals, quasi-drugs, reagents, etc.

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

KOTAI Biotechnologies, Inc. (KOTAI, Osaka, Japan) is a spinout from Osaka University's world leading research center, Immunology Frontier Research Center launched in 2016. Our unique and sophisticated bioinformatics based on deep structure understandings has enabled us to analyze high throughput sequencing data of the immune systems such as Immune repertoire (BCR, TCR, antibodies, etc) and RNA-seq data. KOTAI is working on discoveries of new biomarkers and therapeutic compounds through the repertoire analysis.

Medmain Inc. is a company to develop and provide "PidPort", a pathological AI analysis solution, with a corporate mission of "to create a world where medical services can be accessed with technology anywhere, anytime." "PidPort" is a product that enables the presentation of highly accurate and rapid analysis results by pathology AI developed by deep learning and the online pathological diagnosis such as remote pathological diagnosis. There is a worldwide shortage of "pathologists" who make diagnoses of patients by looking at their tissues and cells to determine whether there is cancer or not and decide the treatment plan, and this has led to serious delays in pathological diagnosis and large regional disparities. With our product "PidPort", we aim to solve this problem and create a world in which patients can receive a high-quality pathological diagnosis immediately wherever they are.

RevolKa is a pioneer of next-generation protein engineering. We are committed to the discovery and development of innovative proteins by leveraging our proprietary artificial intelligence-integrated directed protein evolution technology, called aiProtein®. RevolKa is open to research collaboration opportunities with partners and also co-development of our internal assets. About aiProtein® RevolKa innovatively integrated directed protein evolution with the transformative digital technology, artificial intelligence (AI) to create a proprietary powerful protein engineering technology, called aiProtein®. aiProtein® remarkably accelerates directed protein evolution and enables to create unprecedented engineered proteins. This platform is a robust solution for biologics engineering, for example, to address issues in developability and manufacturability of therapeutic antibodies. aiProtein® enables multi-dimensional simultaneous engineering for protein properties, such as efficacy, affinity, physicochemical properties, immunogenicity, species cross-reactivity, and so on.

Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. Our global business combines our world-leading GPCR-targeted StaR® technology, structure-based drug design and early development capabilities in the UK with a highly experienced clinical development capability and a commercial operation in Japan. We are leveraging these capabilities to generate and advance a broad and deep pipeline of novel medicines across multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases. We intend to develop these opportunities for patients in Japan and globally both internally and through our partnerships with global biopharmaceutical companies and emerging technology companies. Sosei Heptares operates from key locations in Tokyo and Osaka (Japan), London and Cambridge (UK) and Seoul (South Korea). “Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies.